RMD

ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2006

Business Context and Reporting Period

This report covers the fiscal year ended June 30, 2006. ResMed Inc. is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with approximately 2,500 employees and sells products in over 67 countries. Its primary products include airflow generators (CPAP, VPAP, AutoSet), mask systems, and diagnostic devices.

Key Financial Metrics

Note: All share and per-share data reflect a two-for-one stock split effected in September 2005.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 43% to $607.0 million, driven by a 32% organic growth rate, new product launches (Mirage Swift mask, S8 flow generator), and acquisitions (PolarMed, Pulmomed, Saime, Hoefner, Resprecare). Acquisitions contributed $52.7 million in incremental revenue.
• Margin Compression: Gross margin decreased from 65% to 62%. This was attributed to a shift in product mix toward lower-margin flow generators, higher sales in North America (which typically have lower margins than international sales), and the adoption of SFAS 123(R) stock-based compensation accounting.
• Debt Structure: The company converted all $113.25 million of its 4% Convertible Subordinated Notes into common stock in March 2006, eliminating related interest expense. Concurrently, the company entered into a new syndicated facility with HSBC totaling $120.4 million (Tranche A and C) to fund acquisitions and dividend repatriation.
• Accounting Changes: The adoption of SFAS 123(R) resulted in a $15.3 million stock-based compensation expense, reducing net income by approximately $12.0 million on an after-tax basis.

Guidance, Outlook, and Risks

• Outlook: Management expects selling, general, and administrative expenses to remain in the historical range of 31% to 34% of net revenue. Research and development expenses are expected to continue in the range of 5% to 7% of net revenue.
• Strategic Initiatives: The company is expanding into new clinical applications, including the treatment of central sleep apnea and congestive heart failure (VPAP Adapt SV). It is also investing heavily in infrastructure, including a new corporate headquarters in San Diego and expanded R&D facilities in Sydney.
• Key Risks:
  • Reimbursement: Dependence on third-party payers (Medicare, Medicaid, private insurers) creates risk regarding price controls and coverage limitations.
  • Competition: Highly competitive market with major players like Respironics and DeVilbiss; risk of product obsolescence.
  • Regulatory: Subject to FDA and international regulations; delays in clearance could impact new product launches.
  • Foreign Currency: Significant exposure to fluctuations in the Australian dollar and Euro, which impacts reported sales and earnings.
  • Acquisition Integration: Risks associated with integrating recent acquisitions (PolarMed, Pulmomed, Saime) and realizing anticipated synergies.

Investor Verification Checklist

• Acquisition Synergies: Verify the integration progress and revenue contribution of recent acquisitions (Saime, PolarMed, Pulmomed) against management's projections.
• Reimbursement Trends: Monitor changes in Medicare and private payer reimbursement rates for CPAP and VPAP devices, particularly in the U.S. market.
• Product Mix: Track the ratio of flow generator sales to mask/accessory sales to understand future margin trajectory.
• Debt Covenants: Review compliance with financial covenants in the new HSBC syndicated facility and Union Bank revolving credit agreement.
• Stock-Based Compensation: Assess the ongoing impact of SFAS 123(R) on future operating expenses and net income.
• Foreign Exchange: Evaluate the effectiveness of the company's hedging program against AUD and EUR volatility.